SPDR Advertisement SureTrader SureTrader SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

Highlights from AGN’s 1Q11 CC:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 550
Posts 86,921
Boards Moderated 29
Alias Born 09/05/02
160x600 placeholder
Advertisement
Greek, German Tensions Turn to Open Resentment
At newspaper kiosks in Greece, ahead of Sunday's referendum, some front pages this week showed swastikas and the word "OXI", Greek for "no." On the streets of Athens, a poster showed German Finance Minister Wolfgang Schäuble with the words: "He's been sucking your blood for five years. Now tell him NO."
Electrolux's Plan to Buy GE's Appliances Unit Doesn't Worry Major Customers
Antitrust Cops Swing A Big Stick
BP Turns Page on a Dark Chapter
Aetna to Buy Humana -- 4th Update
Intel President Renée James to Leave as Others Also Depart -- Update
Centene to Buy Health Net for $6.3 Billion
Brazil Federal Police Arrest Another Former Petrobras Executive
Train Carrying Toxic Gas Derails in Tennessee
Donald Trump Dropped by NBC After Anti-Immigrant Remarks
DewDiligence Member Level  Wednesday, 05/04/11 03:11:09 PM
Re: DewDiligence post# 114167
Post # of 193157 
Highlights from AGN’s 1Q11 CC:

• 2011 non-GAAP EPS guidance raised by $0.02 to a range $3.56-3.62 (+14% YoY).

• Botox: $365M, +9% YoY in local currencies. Dysport, the main competitor, remains stuck at a 17% procedure share in US cosmetic indications and a de minimis share in US medical indications share (#msg-62706265, #msg-49695053). Xeomin’s US market share in also de minimis. Worldwide in all indications, Botox has an 80% market share.

• Juvederm franchise: $88M, +47% YoY in local currencies, due in part to inventory stocking for a promotional program aimed at patients who used Botox and Juvederm.

• Latisse: $25M, +34% YoY, +47% QoQ in local currencies due to some inventory stocking. Although 1Q11 was on track with AGN’s forecast of 2011 sales of $100M, Latisse is clearly not ramping up as quickly as I expected when the product was approved in late 2008 (#msg-34424441).

• Only weak product was LapBand: $52M, -16% YoY in local currencies; however, LapBand retained a 73% global market share in the category. (JNJ has the rest.)

• Sales of all AGN products in Latin America increased 32% YoY in dollars, thanks in part to the stronger Brazilian Real.

15% of AGN’s overall sales are in emerging markets; CEO, David Pyott thinks this will go to 25-30% in the next five years.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist